Τίτλος:
Comparison of ondansentron versus ondansentron plus methylprednisolone as antiemetic prophylaxis during cisplatin-containing chemotherapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
We compared the antiemetic efficacy of ondansentron versus ondansentron and corticosteroids in cisplatin-induced emesis. None of our patients had received prior chemotherapy. All patients received chemotherapy including cisplatin 100 mg/m2. Forty patients received ondansentron alone (Group A) and 40 the combination of ondansentron and methylprednisolone (Group B). Ondansentron was given at a dose of 8 mg in 100 mL N S over 10 min by intravenous infusion. The initial dose was administered before the cisplatin and was followed by 8 mg orally in the afternoon and before sleeping the first day of chemotherapy. During the next 2 days, the patients received 8 mg orally 3 times daily. Methylprednisolone was given as an intravenous bolus of 40 mg before chemotherapy and then together with each dose of ondansentron at a dose of 16 mg orally. Group A had significantly longer duration of nausea after chemotherapy than group B (117 ± 111 min, 62 ± 71 min, P < 0.013). The response on emesis was also improved in group B, especially the day of chemotherapy [treatment failure: group A: 13 patients (30%) versus group B: 5 patients (11.6%), P <0.03] and the next day [complete response: group A: 17 patients (39.5%) versus group B: 30 patients (69.7%), P < 0.005]. Patients in group B presented more sedative effects (P < 0.001) and better appetite (P < 0.02) than patients in group A. There were no other significant differences in side effects (activity, headache, constipation, etc). We conclude that corticosteroids improve the antiemetic efficacy of ondansentron in cisplatin-induced chemotherapy, and should be included in antiemetic regimens. © 1994.
Συγγραφείς:
Tsavaris, N.
Mylonakis, N.
Bacoyiannis, C.
Katsikas, M.
Lioni, A.
Kosmidis, P.
Περιοδικό:
Journal of Pain and Symptom Management
Λέξεις-κλειδιά:
cisplatin; fluorouracil; methylprednisolone; ondansetron; vinblastine, adult; aged; article; cancer combination chemotherapy; diaphoresis; drug efficacy; drug potentiation; feeding disorder; female; gastrointestinal toxicity; head and neck cancer; headache; human; intravenous drug administration; lung non small cell cancer; major clinical study; male; mesothelioma; nausea; oral drug administration; orthostatic hypotension; ovary cancer; sedation; vomiting; xerostomia, Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Comparative Study; Drug Therapy, Combination; Female; Human; Male; Methylprednisolone; Middle Age; Nausea; Ondansetron; Vomiting
DOI:
10.1016/0885-3924(94)90102-3
